Effectiveness of cognitive behavioural therapy augmentation in major depression treatment (ECAM study)

Study protocol for a randomised clinical trial

Atsuo Nakagawa, Mitsuhiro Sado, Dai Mitsuda, Daisuke Fujisawa, Toshiaki Kikuchi, Takayuki Abe, Yuji Sato, Satoru Iwashita, Masaru Mimura, Yutaka Ono

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Major depression is a serious mental disorder that causes substantial distress and impairment in individuals and places an enormous burden on society. Although antidepressant treatment is the most common therapy provided in routine practice, there is little evidence to guide second-line therapy for patients who have failed to respond to antidepressants. The aim of this paper is to describe the study protocol for a randomised controlled trial that measures the clinical effectiveness of cognitive behavioural therapy (CBT) as an augmentation strategy to treat patients with non-psychotic major depression identified as suboptimal responders to usual depression care. Methods and analysis: The current study is a 16-week assessor-blinded randomised, parallel-groups superiority trial with 12-month follow-up at an outpatient clinic as part of usual depression care. Patients aged 20-65 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Major Depressive Disorder who have experienced at least one failed trial of antidepressants as part of usual depression care, will be randomly assigned to receive CBT plus treatment as usual, or treatment as usual alone. The primary outcome is the change in clinician-rated 17-item GRID-Hamilton Depression Rating Scale (GRID-HAMD) score at 16 weeks, and secondary outcomes include severity and change in scores of subjective depression symptoms, proportion of responders and remitters, safety and quality of life. The primary population will be the intention-to-treat patients. Ethics and dissemination: All protocols and the informed consent form comply with the Ethics Guideline for Clinical Research ( Japanese Ministry of Health, Labour and Welfare). Ethics review committees at the Keio University School of Medicine and the Sakuragaoka Memorial Hospital approved the study protocol. The results of the study will be disseminated at several research conferences and as published articles in peer-reviewed journals. The study will be implemented and reported in line with the CONSORT statement. Trial registration number: UMIN Clinical Trials Registry: UMIN000001218.

Original languageEnglish
Article numbere006359
JournalBMJ Open
Volume4
Issue number10
DOIs
Publication statusPublished - 2014

Fingerprint

Cognitive Therapy
Randomized Controlled Trials
Depression
Antidepressive Agents
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics
Clinical Ethics
Consent Forms
Ethics Committees
Major Depressive Disorder
Advisory Committees
Ambulatory Care Facilities
Research
Mental Disorders
Ethics
Registries
Quality of Life
Medicine
Clinical Trials
Guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effectiveness of cognitive behavioural therapy augmentation in major depression treatment (ECAM study) : Study protocol for a randomised clinical trial. / Nakagawa, Atsuo; Sado, Mitsuhiro; Mitsuda, Dai; Fujisawa, Daisuke; Kikuchi, Toshiaki; Abe, Takayuki; Sato, Yuji; Iwashita, Satoru; Mimura, Masaru; Ono, Yutaka.

In: BMJ Open, Vol. 4, No. 10, e006359, 2014.

Research output: Contribution to journalArticle

@article{ff3082186898415590594b2373e5a298,
title = "Effectiveness of cognitive behavioural therapy augmentation in major depression treatment (ECAM study): Study protocol for a randomised clinical trial",
abstract = "Introduction: Major depression is a serious mental disorder that causes substantial distress and impairment in individuals and places an enormous burden on society. Although antidepressant treatment is the most common therapy provided in routine practice, there is little evidence to guide second-line therapy for patients who have failed to respond to antidepressants. The aim of this paper is to describe the study protocol for a randomised controlled trial that measures the clinical effectiveness of cognitive behavioural therapy (CBT) as an augmentation strategy to treat patients with non-psychotic major depression identified as suboptimal responders to usual depression care. Methods and analysis: The current study is a 16-week assessor-blinded randomised, parallel-groups superiority trial with 12-month follow-up at an outpatient clinic as part of usual depression care. Patients aged 20-65 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Major Depressive Disorder who have experienced at least one failed trial of antidepressants as part of usual depression care, will be randomly assigned to receive CBT plus treatment as usual, or treatment as usual alone. The primary outcome is the change in clinician-rated 17-item GRID-Hamilton Depression Rating Scale (GRID-HAMD) score at 16 weeks, and secondary outcomes include severity and change in scores of subjective depression symptoms, proportion of responders and remitters, safety and quality of life. The primary population will be the intention-to-treat patients. Ethics and dissemination: All protocols and the informed consent form comply with the Ethics Guideline for Clinical Research ( Japanese Ministry of Health, Labour and Welfare). Ethics review committees at the Keio University School of Medicine and the Sakuragaoka Memorial Hospital approved the study protocol. The results of the study will be disseminated at several research conferences and as published articles in peer-reviewed journals. The study will be implemented and reported in line with the CONSORT statement. Trial registration number: UMIN Clinical Trials Registry: UMIN000001218.",
author = "Atsuo Nakagawa and Mitsuhiro Sado and Dai Mitsuda and Daisuke Fujisawa and Toshiaki Kikuchi and Takayuki Abe and Yuji Sato and Satoru Iwashita and Masaru Mimura and Yutaka Ono",
year = "2014",
doi = "10.1136/bmjopen-2014-006359",
language = "English",
volume = "4",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - Effectiveness of cognitive behavioural therapy augmentation in major depression treatment (ECAM study)

T2 - Study protocol for a randomised clinical trial

AU - Nakagawa, Atsuo

AU - Sado, Mitsuhiro

AU - Mitsuda, Dai

AU - Fujisawa, Daisuke

AU - Kikuchi, Toshiaki

AU - Abe, Takayuki

AU - Sato, Yuji

AU - Iwashita, Satoru

AU - Mimura, Masaru

AU - Ono, Yutaka

PY - 2014

Y1 - 2014

N2 - Introduction: Major depression is a serious mental disorder that causes substantial distress and impairment in individuals and places an enormous burden on society. Although antidepressant treatment is the most common therapy provided in routine practice, there is little evidence to guide second-line therapy for patients who have failed to respond to antidepressants. The aim of this paper is to describe the study protocol for a randomised controlled trial that measures the clinical effectiveness of cognitive behavioural therapy (CBT) as an augmentation strategy to treat patients with non-psychotic major depression identified as suboptimal responders to usual depression care. Methods and analysis: The current study is a 16-week assessor-blinded randomised, parallel-groups superiority trial with 12-month follow-up at an outpatient clinic as part of usual depression care. Patients aged 20-65 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Major Depressive Disorder who have experienced at least one failed trial of antidepressants as part of usual depression care, will be randomly assigned to receive CBT plus treatment as usual, or treatment as usual alone. The primary outcome is the change in clinician-rated 17-item GRID-Hamilton Depression Rating Scale (GRID-HAMD) score at 16 weeks, and secondary outcomes include severity and change in scores of subjective depression symptoms, proportion of responders and remitters, safety and quality of life. The primary population will be the intention-to-treat patients. Ethics and dissemination: All protocols and the informed consent form comply with the Ethics Guideline for Clinical Research ( Japanese Ministry of Health, Labour and Welfare). Ethics review committees at the Keio University School of Medicine and the Sakuragaoka Memorial Hospital approved the study protocol. The results of the study will be disseminated at several research conferences and as published articles in peer-reviewed journals. The study will be implemented and reported in line with the CONSORT statement. Trial registration number: UMIN Clinical Trials Registry: UMIN000001218.

AB - Introduction: Major depression is a serious mental disorder that causes substantial distress and impairment in individuals and places an enormous burden on society. Although antidepressant treatment is the most common therapy provided in routine practice, there is little evidence to guide second-line therapy for patients who have failed to respond to antidepressants. The aim of this paper is to describe the study protocol for a randomised controlled trial that measures the clinical effectiveness of cognitive behavioural therapy (CBT) as an augmentation strategy to treat patients with non-psychotic major depression identified as suboptimal responders to usual depression care. Methods and analysis: The current study is a 16-week assessor-blinded randomised, parallel-groups superiority trial with 12-month follow-up at an outpatient clinic as part of usual depression care. Patients aged 20-65 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Major Depressive Disorder who have experienced at least one failed trial of antidepressants as part of usual depression care, will be randomly assigned to receive CBT plus treatment as usual, or treatment as usual alone. The primary outcome is the change in clinician-rated 17-item GRID-Hamilton Depression Rating Scale (GRID-HAMD) score at 16 weeks, and secondary outcomes include severity and change in scores of subjective depression symptoms, proportion of responders and remitters, safety and quality of life. The primary population will be the intention-to-treat patients. Ethics and dissemination: All protocols and the informed consent form comply with the Ethics Guideline for Clinical Research ( Japanese Ministry of Health, Labour and Welfare). Ethics review committees at the Keio University School of Medicine and the Sakuragaoka Memorial Hospital approved the study protocol. The results of the study will be disseminated at several research conferences and as published articles in peer-reviewed journals. The study will be implemented and reported in line with the CONSORT statement. Trial registration number: UMIN Clinical Trials Registry: UMIN000001218.

UR - http://www.scopus.com/inward/record.url?scp=84908145767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908145767&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2014-006359

DO - 10.1136/bmjopen-2014-006359

M3 - Article

VL - 4

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 10

M1 - e006359

ER -